Abstract: According to previous reports, redoxir is an effective drug for the treatment of new coronary pneumonia. A few days ago, the Trump administration purchased more than 500,000 doses of trial drugs from the company that produced Ridesivir, which was 90% of the total production capacity of Gilead in July, August, and September. In the next three months, all countries other than the United States will be unable to buy the new coronary pneumonia treatment drug Ridesivir.
Earlier news came out that remdesivir is an effective drug for the treatment of new coronary pneumonia. A few days ago, the Trump administration purchased more than half a million doses of trial drugs from Gilead, the company that produced ridcive, which is 90% of the total production capacity of Gilead in July, August, and September. Surprisingly, in at least the next three months, all countries except the United States will be unable to buy the new coronary pneumonia drug Radecivir.
The United States purchased more than 500,000 doses of remaining medicines, South Korea hastily signed a contract to guarantee supply
With the first batch of 140,000 doses of trial drugs supplied by the US pharmaceutical company Gilead to the world before. The Trump administration has purchased more than 500,000 doses of remaining medicines. It is expected that in the next three months, it will be difficult for countries other than the United States to buy the treatment drug, and most countries currently have little stock of the medicine .
The report said that health experts from all over the world were shocked by the unilateral "buy out" action of Red West. The Trump administration has stated that once a vaccine is available, it is prepared to purchase at a price and strategy higher than all other countries to ensure that the United States provides the necessary medical supplies.
According to Yonhap News Agency reported on the 1st, the Ministry of Disease Management of South Korea said on the same day that the department recently signed a supply contract of ridsivir with the pharmaceutical importer Gilead Scientific Korea Branch and will officially put the drug into the new crown clinical treatment from now on.
Redoxivir is temporarily assigned to patients with severe pneumonia who require oxygen therapy. The Department of Disease Management plans to first ensure a certain amount of ridxivir under unpaid supply conditions this month, and then start price negotiations with importers next month.
It is reported that the government will introduce Redcive through a special import process. This process refers to the special measures for the Department of Food and Drug Safety to allow relevant departments to import drugs that have not been approved in the country in the event of a public health crisis such as a pandemic.
Prior to the advent of the new crown vaccine, redcive will be an effective drug for the treatment of new crown pneumonia
Redoxir was originally a specific drug for the treatment of Ebola virus, but recent US clinical trials have found that this drug can effectively shorten the recovery time of patients with new coronavirus, which has attracted much attention.
In addition to pricing, the actual efficacy of ridxivir has also been controversial.
On April 29, the international medical journal "The Lancet" published online the results of the world’s first randomized, double-blind, placebo-controlled, multi-center clinical trial of redoxivir in Wuhan, China. Compared with placebo, The antiviral drug ridxivir treatment of critically ill hospitalized patients did not accelerate the recovery rate of patients with new crowns, nor did it reduce the mortality rate.
On the same day, Gilead Science released a positive signal to the outside world and announced two good news. First, the clinical trial from the National Institutes of Health (NIH) has reached the main end point and the data is positive; the second is the announcement of the Gilead open label Of clinical trials showed that at least half of the patients had improved clinical symptoms after 5 days of treatment and were discharged from the hospital, and received 5-day medication and 10-day medication with similar efficacy. With the exception of Italy, the 14-day mortality rate for both groups was only 7%.